Monitor upcoming 12-month sentinel cohort data readout, which will be the first efficacy/safety signals from this large BARDA-funded Phase 2b trial. A positive result could drive significant upside given the stock's small clinical-stage biotech profile, but the funding cut by BARDA signals reduced government enthusiasm for the program. The historical pattern of VXRT reversing initial moves at T+20 (negative drift on neutral reports) suggests caution post-data release.
Price Chart
Executive Summary
Vaxart entered Modification No. 7 to its BARDA Project Agreement, reducing total available funding by ~$116M to ~$345M following a ~50% participant reduction ordered by BARDA in August 2025. The modification releases ~$29M for trial completion and exploratory analyses, enabling Vaxart to report 12-month sentinel cohort data in the coming weeks and main cohort data in first half of 2027. While the funding cut reflects reduced government scope, the trial remains active with over 5,000 participants and near-term data catalysts.
Key Facts
- Total BARDA funding reduced by ~$116M to ~$345M under Modification No. 7
- Approximately 50% participant reduction due to BARDA partial termination ordered on August 5, 2025
- Modification releases ~$29M for trial completion and exploratory safety/efficacy analyses
- Vaxart expects to report 12-month sentinel cohort (400 participants) data in coming weeks
- Main cohort (5,085 participants) data expected in first half of 2027
- Funding includes ~$68M in firm fixed price amounts and remainder for cost reimbursement
Financial Impact
Total available BARDA funding decreased by approximately $116 million to approximately $345 million; $29 million released for trial completion
Risk Factors
- Reduced trial scope may limit statistical power and commercial potential even if positive
- Future milestone payments depend on achieving predefined endpoints under the contract
- No guarantee of positive data; negative or equivocal sentinel results could be severely bearish
- VXRT is a clinical-stage company with no approved products and relies on external funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021833 |
| Exhibit: ex_981693.htm | 0001437749-26-021833 |
| Document: 0001437749-26-021833-index-headers.html | 0001437749-26-021833 |
| Document: 0001437749-26-021833-index.html | 0001437749-26-021833 |
| Document: 0001437749-26-021833.txt | 0001437749-26-021833 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 9w ago | 8-K | $0.4800 $0.5000 | ▲ +4.17% | ▲ +0.79% | $0.4400 (−8.33%) |
Jul 7, 2026 12w ago | 8-K | $0.5500 $0.6000 | ▲ +9.09% | ▲ +5.93% | $0.4400 (−20.00%) |
Jul 6, 2026 12w ago | DEFA14A | $0.6200 $0.5900 | ▼ −4.84% | ▼ −5.69% | $0.4400 (−29.03%) |
Jul 2, 2026 13w ago | DEFA14A | $0.6400 $0.5490 | ▼ −14.22% | ▼ −14.52% | $0.4400 (−31.25%) |
Jul 2, 2026 13w ago | 8-K | $0.6400 $0.5200 | ▼ −18.75% | ▼ −18.34% | $0.4400 (−31.25%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4400 (−22.81%) |
Jun 26, 2026 13w ago | DEFA14A | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4400 (−22.81%) |
Jun 26, 2026 13w ago | 8-K | $0.5700 $0.4501 | ▼ −21.04% | ▼ −20.78% | $0.4400 (−22.81%) |
Jun 16, 2026 15w ago | DEFA14A | $0.5600 $0.5300 | ▼ −5.36% | ▼ −6.21% | $0.4400 (−21.43%) |
Jun 8, 2026 16w ago | DEFA14A | $0.5800 $0.5502 | ▼ −5.14% | ▼ −6.53% | $0.4400 (−24.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access